Onconic Therapeutics (476060.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	82.2B	53.4B	14.8B	21.1B	95.0M
Cost of Revenue	37.5B	27.9B	—	—	—
Gross Profit	44.7B	25.5B	14.8B	21.1B	95.0M
Operating Expenses
R&D Expense	16.1B	9.7B	10.9B	15.8B	13.2B
SG&A Expense	35.4B	28.2B	6.1B	1.2B	492.0M
General & Admin Expense	33.7B	25.9B	4.3B	496.7M	218.1M
Selling & Marketing Expense	575.6M	2.4B	1.8B	706.8M	273.9M
Other Expenses	(18.5B)	(25.1B)	2.6B	1.9B	1.3B
Total Operating Expenses	27.4B	12.9B	19.6B	18.8B	14.9B
Cost and Expenses	64.9B	40.8B	19.6B	18.8B	14.9B
Operating Income (EBIT)	17.3B	12.6B	(4.8B)	2.2B	(14.8B)
Non-Operating
Interest Income	1.5B	1.4B	942.6M	863.0M	31.5M
Interest Expense	9.0M	11.7M	664.2M	1.8B	904.4M
Net Interest Income	1.5B	1.4B	278.5M	(912.7M)	(872.9M)
Other Non-Op Income/Expense	4.9B	1.1B	(5.1B)	(1.6B)	405.6M
Non-Operating Income (excl Interest)	(2.1B)	—	4.5B	(206.6M)	(1.3B)
EBT (Pre-Tax Income)	22.2B	13.7B	(9.9B)	661.8M	(14.4B)
Income Tax Expense	(2.0B)	(2.1B)	(1.8B)	(1.0B)	—
Bottom Line
Net Income	24.3B	15.8B	(8.1B)	1.7B	(14.4B)
Earnings from Cont. Ops	24.3B	15.8B	(8.1B)	1.7B	(14.4B)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	24.3B	15.8B	(8.1B)	1.7B	(14.4B)
Per Share
Basic EPS	₩543	₩359	(₩990)	₩291	(₩24,969)
Diluted EPS	₩538	₩359	(₩990)	₩291	(₩24,969)
Revenue Per Share	₩1,813	₩1,200	₩1,815	₩3,642	₩164
Shares
Basic Shares Outstanding	45.3M	44.5M	8.2M	5.8M	577993
Diluted Shares Outstanding	45.8M	44.5M	8.2M	5.8M	577993
Profitability Metrics
EBITDA	19.0B	13.1B	(8.8B)	2.9B	(13.3B)
D&A	567.3M	528.4M	452.7M	460.1M	200.8M
EBIT	18.4B	12.6B	(9.3B)	2.4B	(13.5B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026